Phase 3 N=25 Theca Cell Function in Women With Polycystic Ovary Syndrome (PCOS)
Polycystic Ovary Syndrome
Primary: Serum 17OHP Responses to hCG — 2.0; 1.2; 1.1; 1.0 ng/ml — p=<0.05
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=575 Effects of Phenylephrine Extended-Release Tablets on Allergy-Related Nasal Congestion (P08498 AM1)
Seasonal Allergic Rhinitis
Primary: Mean Change From Baseline in Daily Reflective Nasal Congestion Score — 2.357; 2.271; -0.394; -0.412 Scores on a scale
Phase 3 N=707 Multicenter Study of the Safety and Efficacy of NAFT-500 in Tinea Pedis
Tinea Pedis · Athlete's Foot
Primary: Percentage of Subjects With Complete Cure at Week 6. — 17.7; 7.1; 16.1; 3.1 percentage of subjects with complete cur — p=0.010
N/A N=131 A Study of Continuous Oral Contraceptives and Doxycycline
Contraceptives, Oral
Primary: Differences in Bleeding Patterns Between Study Groups. — 26.72; 31.86; 25.69; 18.84 days
N/A N=208 Cap-assisted Water Immersion Versus Water Immersion Colonoscopy
Colonoscopy
Primary: Cecal Intubation Time — 6.9; 7.4 minutes
Phase 1 N=46 A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Inhaled Montelukast (MK-0476) in Participants With Mild or Moderate Asthma (MK-0476-380 AM3)(COMPLETED)
Asthma
Primary: Number of Participants Who Experienced At Least One Adverse Event — 2; 4; 6; 9 participants
Phase 3 N=142 Evaluation of the Efficacy and Safety of Diclofenac HPBCD 75mg/ml in Treatment of Pain Following Dental Surgery
Dental Pain
Primary: Pain Intensity Difference (PID) — 44.8; 45.5 mm — p=0.813
Phase 3 N=306 Evaluation of the Efficacy and Safety of Diclofenac HPBCD 25, 50 mg/ml in the Treatment of Post-surgical Pain Following Dental Surgery
Dental Pain
Primary: Pain Intensity Difference (PID) on a 0-100 VAS — 36.5; 37.3; 37.7; 12.3 mm — p=< 0.001
Phase 4 N=340 Efficacy And Safety Of Parecoxib 40mg vs. Ketoprofen 100mg In The Management Of Acute Renal Colic
Pain
Primary: Mean Pain Intensity Difference at 30 Minutes (mPID30min) — 34.147; 35.266 mm
Phase 3 N=326 Trial of Microplasmin Intravitreal Injection for Non-surgical Treatment of Focal Vitreomacular Adhesion. The MIVI-TRUST (TG-MV-006) Trial.
Vitreomacular Adhesion
Primary: Proportion of Subjects With Nonsurgical Resolution of Focal Vitreomacular Adhesion at Day 28. — 27.9; 13.1 percentage of participants — p=0.003
Phase 2 N=6 Cephalon Decitabine, Arsenic Trioxide and Ascorbic Acid for Myelodysplastic Syndrome
Myelodysplastic Syndrome
Primary: Number of Patients With an Overall Response of Complete Response (CR) or Partial Response (PR) — 0 participants
N/A N=420 Combination of Water Immersion and Carbon Dioxide Insufflation for Minimal Sedation Colonoscopy
Colonoscopy
Primary: Success Rate of Minimal Sedation Colonoscopy
Phase 4 N=24 Ziprasidone for Clozapine- or Olanzapine-Associated Diabetes Mellitus
Schizophrenia
Primary: Change From Baseline in Fasting Glucose — 5; -4.5 mg/dL — p=0.956
Phase 1 N=12 Interpersonal Psychotherapy for Depressed Adolescents Engaging in Non-suicidal Self-injury
Depression · Self-injurious Behavior
Primary: CGI
Phase 4 N=15 A Placebo-Controlled, Cross-Over Trial of Aripiprazole
Schizophrenia
Primary: Change From Baseline in Weight (Lbs) — -2.9; 2.1 lbs — p=0.003